Work

Neurocognitive function and quality of life results from a phase II study (NRG/RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas.

Year: 2026

Type: article

Source: PubMed

DOI: 10.1016/j.ijrobp.2026.10.031

Authors: Jeffrey S Wefel, Stephanie L Pugh, Ali K Choucair, Barbara J Fisher, C Leland Rogers, Tom Mikkelsen, Jon Glass, Hsiang-Hsuan Michael Yu, H Ian Robins, Minhee Won, Minesh P Mehta, Benjamin Movsas

Institutions: The University of Texas MD Anderson Cancer Center, NRG Oncology, Aurora Health Care, Henry Ford Health, Henry Ford Hospital, Thomas Jefferson University, Moffitt Cancer Center, University of Wisconsin–Madison, Florida International University

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7225651855

FWCI:

Cites:

Cited by:

Related to: 10